2016 American Transplant Congress
Variation in Co-Medication Use According to Kidney Transplant Immunosuppressive Regimen: Application of Integrated Registry and Pharmacy Claims Data.
Background: While modern immunosuppressive therapies (ISx) have substantially reduced acute rejection, ISx medications have many side effects, and transplant recipients must take an array of…2016 American Transplant Congress
Efficacy and Renal Function in Kidney Transplant Recipients Receiving Tacrolimus (TAC)-Based Immunosuppressive Regimens in Combination with Everolimus (EVR) versus Mycophenolate (MPA).
Nephrology Division, Hospital do Rim - UNIFESP, Sao Paulo, Brazil.
Acute rejection and renal function are associated with long-term renal allograft survival. We evaluated these outcomes in patients receiving reduced TAC exposure combined with EVR…2016 American Transplant Congress
Impact on Renal Function of Stepwise Withdrawal of Tacrolimus Combined with Everolimus and EC-MPS vs Standard Treatment Combining Tacrolimus and EC-MPS in De Novo Liver Transplant Recipients: Results of the SIMCER Study.
Introduction: Long-term post-liver transplant (LTx) complications, particularly impaired renal function (RF) and its consequences, remain a concern. Presented here are the results of the SIMCER…2016 American Transplant Congress
Ibrutinib Suppresses Alloantibody Responses in A Mouse Model of Allosensitization: A Preliminary Report.
CTC/Surgery, Cedars-Sinai Medical Center, Los Angeles, CA.
Background Ibrutinib is a Bruton tyrosine Kinase (BTK) antagonist that inhibits B cell receptor (BCR) signaling, therefore blocking B cell activation. Ibrutinib is approved by…2016 American Transplant Congress
Refill-Based Immunosuppression Non-Adherence Is Associated with Increased Death Censored Graft Loss.
Medicine, University of Alberta, Edmonton, AB, Canada.
Introduction Medication non-adherence is a major contributor of graft loss in kidney transplant(KTX) recipients. We aim to evaluate the association of immunosuppression non-adherence to graft…2016 American Transplant Congress
Comparison of Low Dose and Very Low Dose Extended-Release Tacrolimus / MMF in De Novo Kidney Transplant Recipients.
Recently, once-daily tacrolimus extended-release formulation (TACER) has been accepted in kidney transplantation, however its optimal dosing are not well evaluated. We have validated low dose…2016 American Transplant Congress
Calcineurin Inhibitor (CNI) Delay with ATG Induction: Teaching an Old Dog, New Tricks.
CNI delay early after heart transplantation is a recommended therapeutic option according to ISHLT guidelines. However, there exist only few published data on feasibility of…2016 American Transplant Congress
IVIG and High Dose Steroid Treatment of Transplant Glomerulopathy Effectively Slows Progression of Loss of Renal Allograft Function.
Introduction Transplant glomerulopathy (TG) is commonly associated with chronic antibody mediated rejection and is a major cause of late kidney allograft loss with no established…2016 American Transplant Congress
Contrasting Effects of Tacrolimus and Everolimus on Regulatory T Cell Activation and Mixed Hematopoietic Chimerism Induced by Natural Killer T Cell Stimulation.
Calcineurin (CN)-dependent IL-2 production is crucial for regulatory T cells (Tregs) to demonstrate suppressive activity. The mTOR signal is not required for Treg function because…2016 American Transplant Congress
Pre-Transplant Risk Factors: Predicting Nonadherence and Rejection in Adult Liver Transplant Recipients.
Purpose: The pre-liver transplant (LT) psychosocial evaluation aims to identify risk factors for immunosuppression nonadherence (NA) and poor post-LT outcomes. Despite broad support for these…
- « Previous Page
- 1
- …
- 116
- 117
- 118
- 119
- 120
- …
- 138
- Next Page »